Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?

Author(s): Rosario Cianci, Alessandro Zuccala, Gaetano Lucisano, Biagio Barbano, Paola Martina, Antonietta Gigante, Gianfranco Clemenzia, Giorgio Fuiano

Journal Name: Current Vascular Pharmacology

Volume 11 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Renal artery stenosis (RAS) is a cause of hypertension and ischemic nephropathy. The incidence of this disorder is probably less than 1% in patients with mild hypertension, but rises to as high as 10 to 40% in patients with acute, severe or refractory hypertension. Significant RAS can be caused by atheromatous plaques, or due to fibromuscular dysplasia (FMD). Atherosclerotic lesions are present in almost 7% of adults older than 65 years and up to 50% of patients presenting with diffuse atherosclerotic disease. In contrast to atherosclerosis, FMD most often affects women under the age of 50 and typically involves the distal main renal artery or the intrarenal branches. The optimal treatment for RAS is not yet established. Based on recent trials, we reviewed the literature on pharmacological and endovascular treatment of atherosclerotic RAS and ischemic nephropathy.

Keywords: Ischemic nephropathy, percutaneous revascularization, renal artery stenosis, renin angiotensin aldosterone system, renovascular hypertension.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 17 July, 2013
Page: [531 - 542]
Pages: 12
DOI: 10.2174/1570161111311040017
Price: $65

Article Metrics

PDF: 11